Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Annals of Oncology

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDL500PMID 17301071
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study.

  2006influential reference
• Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.

  2006cited by this paper
• Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer.

  2005cited by this paper
• [Standards, options and recommendations for the management and initial care of patients with malignant epithelial ovarian tumors (abridged version)].

  2001cited by this paper
• Prognostic Value of CA125 Kinetics and Half-Life in Advanced Ovarian Cancer

  2000cited by this paper
• Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.

  1995cited by this paper
• Use of CA‐125 response to predict survival parameters of patients with advanced ovarian carcinoma

  1994cited by this paper
• The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

  1993cited by this paper
• Prognostic value of CA 125 in advanced ovarian cancer.

  1992cited by this paper
• Early serum CA125 response and outcome in epithelial ovarian cancer.

  1990cited by this paper
• Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses.

  1990cited by this paper
• Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.

  1989cited by this paper
• CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer.

  1989cited by this paper
• Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy.

  1988cited by this paper

• Ascites and Serum Interleukin-10 Levels as a Prognostic Tool for Ovarian Cancer Outcomes

  2024cites this paper
• Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response

  2023cites this paper
• Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer

  2022cites this paper
• Prediction effects of serum CA125 decrease ratio during different cycles in relapsed ovarian cancer

  2019cites this paper
• The diagnostic, prediction of postoperative recurrence and prognostic value of HE4 in epithelial ovarian cancer.

  2018cites this paper
• The Effect of CA125 Nadir Level on Survival of Advanced-Stage Epithelial Ovarian Carcinoma after Interval Debulking Surgery

  2017cites this paper
• The Application of CA 125 in the Diagnosis and Follow up of Ovarian Cancer

  2016influential citation
• Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer

  2016influential citation
• КЛИНИЧЕСКАЯ ЗНАЧИМОСТЬ БИОЛОГИЧЕСКИХ МАРКЕРОВ ПРИ РАКЕ ЯИЧНИКОВ, РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, КОЛОРЕКТАЛЬНОМ РАКЕ

  2016cites this paper
• CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review

  2016cites this paper
• Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases

  2015cites this paper
• A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment.

  2014cites this paper
• A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer

  2014cites this paper
• Patient-Derived Xenografts as Pre-clinical Models of Response to Chemotherapy

  2014cites this paper
• Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer

  2014cites this paper
• Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer

  2013cites this paper
• Prise en charge diagnostique et thérapeutique des tumeurs épithéliales malignes de l’ovaire dans le centre ouest-africain de lutte contre le cancer de Dakar

  2013cites this paper
• Pleural cancer antigen-125 levels in benign and malignant pleural effusions.

  2013cites this paper
• Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer

  2012cites this paper
• Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer.

  2012cites this paper
• Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.

  2011cites this paper
• Reduced CMTM5 Expression Correlates With Carcinogenesis in Human Epithelial Ovarian Cancer

  2011cites this paper
• [Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer].

  2011cites this paper
• Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels.

  2011cites this paper
• Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer

  2011cites this paper
• Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer

  2010cites this paper
• CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.

  2010cites this paper
• Utilidad clínica de los marcadores tumorales

  2010cites this paper
• 血清细胞角蛋白19在预测进展期非小细胞肺癌患者化疗疗效及预后中的临床意义

  2010cites this paper
• Biomarkers in Cancer

  2010cites this paper
• Mutations du gène HFE dans le cancer épithélial de l'ovaire

  2009cites this paper
• Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature

  2009influential citation
• Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels.

  2009cites this paper
• Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.

  2009cites this paper
• An Outlook on Ovarian Cancer and Borderline Ovarian Tumors: Focus on Genomic and Proteomic Findings

  2009cites this paper
• L’avenir des marqueurs tumoraux : l’exploitation de leur cinétique. Étude CNBH 2004–2006, de la rédaction d’un cahier des charges aux essais des logiciels existants

  2008cites this paper
• Cancer antigen 125 and prognosis

  2008cites this paper
• Ovarian cancer biomarkers: current options and future promise.

  2008cites this paper
• Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer

  2008cites this paper
• The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer

  2007cites this paper
• Ovarian Cancer Biomarkers: A Focus on Genomic and Proteomic Findings

  2007cites this paper
• Quels marqueurs circulants pour quels cancers?

  2007cites this paper
• Principaux marqueurs circulantsutilisables en cancérologie

  2007cites this paper
• Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma.

  2007cites this paper